Inogen (INGN) Projected to Post Earnings on Thursday

Key Points

• Inogen will report Q1 2026 results after the close on May 7, 2026, with analysts projecting EPS of ($0.24) and revenue of $82.35 million and a conference call scheduled for 5:00 PM ET.
• Inogen's last quarter (reported Feb. 24) beat EPS estimates at ($0.26) while revenue was $81.72 million, but the company remains unprofitable with negative net margin and ROE; analysts forecast about ($1.00) EPS for the current fiscal year and $0 for the next.
• Shares trade near $7.00 with a market cap of ~$191 million and high institutional ownership (~89.9%), and the analyst consensus is a Moderate Buy with an average price target of $11.00.

Inogen (NASDAQ:INGN - Get Free Report) is expected to release its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect Inogen to post earnings of ($0.24) per share and revenue of $82.35 million for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 5:00 PM ET.

Inogen (NASDAQ:INGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 24th. The medical technology company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.10. The company had revenue of $81.72 million during the quarter, compared to analyst estimates of $82.00 million. Inogen had a negative net margin of 6.52% and a negative return on equity of 11.56%. On average, analysts expect Inogen to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Inogen Price Performance

Shares of Inogen stock opened at $7.00 on Thursday. The company has a 50-day moving average of $6.40 and a 200 day moving average of $6.73. The firm has a market cap of $191.31 million, a price-to-earnings ratio of -8.14 and a beta of 1.70. Inogen has a 1 year low of $5.34 and a 1 year high of $9.13.

Institutional Trading of Inogen

Institutional investors and hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN increased its stake in Inogen by 46.2% during the 4th quarter. Wells Fargo & Company MN now owns 26,666 shares of the medical technology company's stock valued at $179,000 after purchasing an additional 8,431 shares in the last quarter. Algert Global LLC increased its stake in Inogen by 22.8% during the 3rd quarter. Algert Global LLC now owns 21,100 shares of the medical technology company's stock valued at $172,000 after purchasing an additional 3,920 shares in the last quarter. Occudo Quantitative Strategies LP bought a new stake in Inogen during the 4th quarter valued at about $145,000. Russell Investments Group Ltd. increased its stake in Inogen by 18.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 17,056 shares of the medical technology company's stock valued at $139,000 after purchasing an additional 2,717 shares in the last quarter. Finally, Brooklyn Investment Group bought a new stake in Inogen during the 3rd quarter valued at about $106,000. 89.94% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Freedom Capital upgraded shares of Inogen to a "strong-buy" rating in a research note on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Inogen currently has a consensus rating of "Moderate Buy" and an average price target of $11.00.

About Inogen

Inogen, Inc NASDAQ: INGN is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company's core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen's offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen's flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.